Most people only think about blood when it is spilled or when a lab tech circles a number in red. SeraGene Therapeutics thinks about it like a system you can tune before anything goes sideways, turning coagulation into something programmable instead of something you pray stays balanced. The name fits. Serum plus genes equals a company rewriting how we approach bleeding disorders without ever having to brag about it.
SeraGene Therapeutics started in 2022 as a spin-out of the Nanomedicines Innovation Network in Canada with scientific roots stretching across the Versiti Blood Research Institute in Wisconsin and the Center for Blood Research at the University of British Columbia. That means real infrastructure, real data and real models, not a pitch deck masquerading as a pipeline.
The founding crew is the kind of scientific lineup that makes investors sit straighter. Dr. Christian Kastrup, Dr. Lih Jiin Juang, Dr. Amy Wong Strilchuk and Dr. Katherine Badior built the platform from years in hematology, RNA therapeutics and blood biochemistry. When Dr. Erika Siren took the CEO seat in 2024 after her time with Takeda, UBC and academic work across Toronto, Vancouver and Harvard Medical School, the rare disease and women’s health focus sharpened into a clear strategy instead of a footnote.
Pathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation, saw enough traction to lead an early investment with Hextwo Capital right beside them. Around that core you have serious supporters like Adage Capital Partners, Blue Owl Healthcare Opportunities, Boxer Capital, Commodore Capital, Deep Track Capital, Foresite Capital and Logos Capital. Big wallets do not move like that unless the science holds up.
The bet is on clot-modifying siRNAs packaged in LNPs, injected, delivered to the liver and tuned to adjust the fibrinolytic pathway. Switch plasminogen down here, boost expression there and suddenly you are talking about long acting prophylaxis that lasts weeks from a single dose. That is more than 10x longer than some current standards and a completely different experience for people with bleeding disorders.
The lead program, SG-001, already showed promising nonhuman primate data at ASH 2024. Eight patented assets sit behind it covering antifibrinolytic RNA-LNP approaches, mRNA for rare bleeding disorders, ADAMTS13 and fibrinogen knockdown and PAI-1 modulation. It is a pipeline built for scale, not a single lucky shot.
Look at the landscape through their lens and clarity hits fast. VWD, hemophilia, rare factor deficiencies, platelet dysfunction, thrombosis and cardiovascular disease all become touchpoints for long duration, liver targeted RNA control. Add the reality that women and girls are disproportionately impacted by uncontrolled bleeding and you begin to understand why Dr. Erika Siren keeps drilling this focus into the company’s direction.
Awards, investor programs and recognition have stacked early. Company to Watch by Life Sciences BC in 2024, Coup de Coeur at Sweet Pharma Day, a spot in the Life Sciences BC Investor Readiness Program, a finalist position in the Eli Lilly Grand Challenge and an early Amgen Golden Ticket from UBC. Momentum like that does not bluff.
If you work anywhere near hematology, rare disease, women’s health or cardiovascular care, SeraGene Therapeutics is a name that will keep showing up until you finally lean in. The science is tight, the team is sharper and the opportunity is still early enough that the story has room to run.
Startups Startup Funding Venture Capital Biotech Biotechnology Healthcare Health Tech Blood Blood Health Data Data Driven Infrastructure Technology Innovation Tech Ecosystem Startup Ecosystem
